PRIVATE PORTFOLIO COMPANIES

Afyx Therapeutics is developing a new therapy for diseases of the oral cavity, using technology based on the Rivelin® clobetasol patch which, uniquely, adheres to mucosal surfaces in order to deliver medicines. The first product candidate, which is in late-stage clinical development, targets oral lichen planus (OLP), for which there is currently no approved treatment.

Akamis Bio (former PsiOxus) is developing gene-based, immunooncology treatments for solid tumours, using its proprietary, intravenously administered T-SIGn virus platform. The portfolio of differentiated gene therapy products are all delivered systemically but act locally within the tumour. The company has several programmes in clinical trials.

Cytoki Pharma is a biotechnology company focused on serious diseases caused by epithelial injury with unmet medical needs. The company’s lead programme is a long- acting interleukin22 for use in inflammatory disease, and other pathologies related to epithelial tissue injury.

Dysis markets high-resolution, digital colposcopes with an adjunctive map overlaid on a live image of the cervix, to help with identification of the most relevant biopsy sites when cancerous and pre-cancerous cervical cancer lesions are suspected.

The company´s commercial performance in 2022 was challenged, partly due to COVID-19 related impact limiting access to customers in the USA and partly due to unfavourable underlying market dynamics in the USA.

Enterome is pioneering the development of novel microbiome-inspired peptide drugs. Enterome is in Phase II studies in several oncology indications, as well as Crohn’s disease.

Folium Science uses CRISPR technology to precisely manage microbial and bacterial populations to enhance soil, animal, plant and, ultimately, human health, in the agriculture, food and beverage industries. The company continues in its quest to bring its technology to the food and feed industries and to launch the first product for controlling salmonella in industrial chicken feed.

Progressing a pipeline of gene therapy programmes based on the company’s AAV10 platform. The lead programme targets treatment of the cardiomyopathy that occurs in patients suffering from the genetic disorder Friedreich’s ataxia (FA).

Based on world-leading electrophysiology science, NMD Pharma develops innovative medical treatments for rare neuromuscular diseases. The company’s lead programme has completed a Phase I/IIa clinical trial in patients with myasthenia gravis.

SNIPR Biome is a clinical-stage company developing new therapies based on the CRISPR gene technology. The company’s technology enables gene therapy of the microbiome or precision killing of bacteria. The lead clinical product is designed to prevent bloodstream infections caused by fluoroquinoloneresistant E. coli.

. Sorriso is developing gastrointestinal tract-restricted antibodies to treat inflammatory bowel disease (IBD) and other inflammatory diseases. Its lead candidate is in Phase II development.

Clinical candidate VMX-C001 is intended to safely and effectively restore haemostasis in case of bleeding or emergency surgery in patients taking oral factor Xa inhibitors.

Vesper Bio is developing new products focused on central nervous system and peripheral diseases. The lead programme, targeting frontotemporal dementia, is currently in preclinical development.